A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest

被引:2
|
作者
Hummel, John [1 ]
Houmsse, Mahmoud [1 ]
Tomassoni, Gery [2 ]
Nair, Devi [3 ]
Romero, Jorge [4 ,5 ]
Hargrove, Joe [3 ]
Mathews, Kiran [6 ]
Thakkar, Anjali B. [7 ]
Ullery, Steven [8 ]
Eapen, Zubin J. [6 ]
Kumar, Uday N. [6 ]
Mehran, Roxana [9 ]
Butler, Javed [10 ,11 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[2] Baptist Hlth Lexington, Lexington, KY USA
[3] St Bernards Heart & Vasc Ctr, Jonesboro, AR USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA
[5] Cardiol & Med Clin, Little Rock, AR USA
[6] Element Sci Inc, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA USA
[8] NAMSA, Minneapolis, MN USA
[9] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
[10] Baylor Scott & White Res Inst, 3434 Live Oak St, Dallas, TX 75204 USA
[11] Univ Mississippi, Dept Med, Jackson, MS USA
关键词
machine learning; sudden cardiac arrest; ventricular arrhythmia; wearable cardioverter defibrillator fi brillator; DEATH; PREVENTION; DISEASE;
D O I
10.1016/j.jacc.2024.04.063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND For many patients, sudden cardiac arrest (SCA) risk is elevated temporarily. Wearable cardioverterdefibrillators (WCDs) can monitor and treat SCA during these temporary periods. Traditional WCDs can be uncomfortable, require frequent maintenance, and cannot be used when showering, resulting in poor compliance and avoidable SCA deaths. The Jewel is a novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) with a machine learning detection algorithm designed to improve compliance and protection against SCA. OBJECTIVES This study aims to demonstrate the safety and clinical effectiveness of a novel P-WCD. METHODS The Jewel IDE Study, a prospective, single-arm study conducted at 30 U.S. sites, enrolled patients at SCA risk due to ventricular tachycardia/ventricular fibrillation who were not candidates for or refused an implantable defibrillator. The primary safety endpoint was <15% patients with clinically significant cutaneous adverse device effects and the primary effectiveness endpoint was <2 inappropriate shocks/100 patient-months. Secondary endpoints were >= 1 successful ventricular tachycardia/ventricular fibrillation conversion and wear time compliance of >14.1 h/d. RESULTS A total of 305 patients (mean age: 57.9 years; 30.2% female, 27.9% non-White) were enrolled, of which 290 had available device data. The clinically significant cutaneous adverse device effect rate was 2.30% (upper 1-sided 98% CI: 4.80); none were severe. No device-related deaths or serious adverse events were reported. The inappropriate shock rate was 0.36/100 patient-months (upper 1-sided 98% CI: 1.53). Of 11 shocks in 9 patients, 9 shocks were adjudicated to be appropriate. Eight of 9 shocks were successful with a single shock. Median wear time compliance was 23.5 (20.7-23.9) h/d. CONCLUSIONS The novel P-WCD is a safe and effective WCD with high patient compliance. There were no deaths due to noncompliance and a high number of successful conversions (Jewel IDE study [A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest]; NCT05201495) (J Am Coll Cardiol 2024;84:525-536) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:525 / 536
页数:12
相关论文
共 50 条
  • [41] Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation
    Sandner, SE
    Wieselthaler, G
    Zuckermann, A
    Taghavi, S
    Schmidinger, H
    Pacher, R
    Ploner, M
    Laufer, G
    Wolner, E
    Grimm, M
    CIRCULATION, 2001, 104 (12) : I171 - I176
  • [42] Underutilization of β-Blockers in Patients Undergoing Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Procedures
    Hauptman, Paul J.
    Swindle, Jason P.
    Masoudi, Frederick A.
    Burroughs, Thomas E.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (02): : 204 - 211
  • [43] Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry
    El-Battrawy, Ibrahim
    Kovacs, Boldizsar
    Dreher, Tobias C.
    Klein, Norbert
    Rosenkaimer, Stephanie
    Roger, Susanne
    Kuschyk, Jurgen
    Saguner, Ardan Muammer
    Kowitz, Jacqueline
    Erath, Julia W.
    Duru, Firat
    Akin, Ibrahim
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [44] Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis
    Hamon, David
    Algalarrondo, Vincent
    Gandjbakhch, Estelle
    Extramiana, Fabrice
    Marijon, Eloi
    Elbaz, Nathalie
    Selhane, Dounia
    Dubois-Rande, Jean-Luc
    Teiger, Emmanuel
    Plante-Bordeneuve, Violaine
    Damy, Thibaud
    Lellouche, Nicolas
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 562 - 568
  • [45] Refractory Vasospastic Angina and Sudden Cardiac Arrest: Is Implantable Cardioverter Defibrillator Indicated and Is It Always Protective?
    Riaz, Sana
    Raj, Vijay
    Shah, Siddharth
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (08)
  • [46] Implantable Cardioverter-Defibrillator Therapy in Patients With Ventricular Fibrillation out of Hospital Cardiac Arrest Secondary to Acute Coronary Syndrome
    Madhavan, Malini
    Friedman, Paul A.
    Lennon, Ryan J.
    Prasad, Abhiram
    White, Roger D.
    Sriram, Chenni S.
    Gulati, Rajiv
    Gersh, Bernard J.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (02):
  • [47] Effectiveness, efficacy, and safety of wearable cardioverter-defibrillators in the treatment of sudden cardiac arrest - Results from a health technology assessment
    Aidelsburger, Pamela
    Seyed-Ghaemi, Janine
    Guinin, Christian
    Fach, Andreas
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (04) : 363 - 371
  • [48] Implantable cardioverter-defibrillator and cardiac resynchronization therapy in patients with left ventricular noncompaction
    Kobza, Richard
    Steffel, Jan
    Erne, Paul
    Schoenenberger, Andreas W.
    Huerlimann, David
    Luescher, Thomas F.
    Jenni, Rolf
    Duru, Firat
    HEART RHYTHM, 2010, 7 (11) : 1545 - 1549
  • [49] Implantable cardioverter-defibrillator therapy in device recipients who survived a cardiac arrest associated with a reversible cause
    Gupta, Aman
    Pasupula, Deepak Kumar
    Bhonsale, Aditya
    Kancharla, Krishna
    Wang, Norman C.
    Adelstein, Evan
    Jain, Sandeep
    Saba, Samir
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2018, 29 (10) : 1413 - 1417
  • [50] The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients
    Erath, Julia W.
    Vamos, Mate
    Sirat, Abdul Sami
    Hohnloser, Stefan H.
    CLINICAL RESEARCH IN CARDIOLOGY, 2017, 106 (04) : 300 - 306